BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...
Case-cohort study designs represent a cost-effective and efficient strategy for analysing time-to-event data, particularly when the event of interest is rare. By selecting a random subcohort along ...
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today ...
Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study ...
Objective Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and primarily affects the joints. While ...
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% ...
Objectives We explored whether a spike in running distance during a single session or over 1 week, compared with the preceding period, was associated with increased risk of running-related overuse ...
Zacks Small Cap Research on MSN
AEMD: Hitting key milestones as company advances clinical study
By M. Marin NASDAQ: AEMD READ THE FULL AEMD RESEARCH REPORT DSMB recommends AEMD progress clinical trial to the final third cohort Aethlon Medical (NASDAQ: AEMD) announced today that the independent ...
Background People have come to rely on restaurants and takeaway foods, and less on cooking at home. We examined the ...
Aethlon Medical (NASDAQ: AEMD) advances to final cohort in oncology trial after positive DSMB review, supporting the safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results